|
|
|
FULC - Fulcrum Therapeutics, Inc
Fulcrum Therapeutics Inc (FULC) is a clinical-stage biopharmaceutical company that focuses on developing small molecule therapies for genetically defined diseases. The company was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics has developed a proprietary platform to identify drugs that selectively modulate gene expression. The platform is called Product Engine and it leverages the latest advances in genomics, gene regulation, and computational biology to identify the key drivers of specific diseases. The company's lead product candidate, losmapimod, is being developed for the treatment of facioscapulohumeral muscular dystrophy (FSHD), a genetic disorder that causes progressive muscle weakness and wasting.
In addition to losmapimod, Fulcrum Therapeutics has a number of other programs in development, including therapies for sickle cell disease, beta thalassemia, and other serious genetic diseases. The company has partnerships with several leading academic institutions and research organizations to advance its programs.
Fulcrum Therapeutics went public in July 2019 and trades on the NASDAQ exchange under the ticker symbol FULC. The company's management team includes experienced biotech executives and scientists who are focused on delivering new treatments for patients with genetic diseases.
|
|
|
|
|
